Abstract. Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic. To treat acute myeloid leukemia, calicheamicin has been conjugated to an antibody that recognizes CD33 (gemtuzumab ozogamicin). The application range of this 'active' targeting strategy is limited since it depends on specific antigen expression by tumor cells. This limitation could be reduced by using an antigen-independent 'passive targeting' strategy for calicheamicin. 'Passive targeting' relies on the dysfunctional vasculature of a neoplastic tumor that allows enhanced retention of macromolecules. We studied the efficacy of calicheamicin conjugated to various carrier molecules: i.e. immunoglobulin, albumin or PEGylated Fc fragments. In nude mice, a conjugate of anti-CD33 and calicheamicin accumulates in human tumor xenografts in the absence of detectable amounts of targeting antigen. Passive targeting provided sufficient accumulation of this conjugate to inhibit tumor growth of 10 different CD33-negative xenograft models. This efficacy depended on the use of an acidlabile linker between antibody and calicheamicin. Substitution of immunoglobulin as a carrier with either albumin or PEGylated Fc reduced or eliminated the efficacy of the conjugate. The results showed that using 'non-specific' immunoglobulin for passive targeting of calicheamicin might be an effective mode of cancer therapy.
Introduction
The low therapeutic index of cytotoxic chemotherapy used for cancer treatment prevents administration of sufficiently high doses necessary to eradicate a tumor. To circumvent this problem, several drug delivery strategies involving macromolecular or particulate carriers have been designed to produce cancer selective therapeutics (1). A passive targeting strategy relies on the enhanced permeability and retention effect (EPR) (2) of a tumor. This effect allows accumulation of particles or water-soluble macromolecules in a tumor because of the leakiness of the fenestrated endothelium of its blood vessels combined with inadequate lymphatic drainage. Examples of carriers used for this mode of targeting are liposomes (3), albumin (4), dextran (5) or poly(ethylene glycol) (PEG) polymers (6) .
For an active tumor targeting strategy (1), the carrier needs a targeting component that specifically interacts with select cells or cell matrix components in a tumor. Specific antibodies that recognize tumor-associated antigens (TAA) are well studied and clinically used carriers for active tumor targeting. In this regard, we developed a conjugate [gemtuzumab ozogamicin, GO (7)] of the disulfide derivative N-acetyl Á calicheamicin dimethyl hydrazide (CalichDMH) and the anti-CD33 antibody, hP67.6. CalichDMH is a semi-synthetic calicheamicin that qualifies as a potent double-stranded DNA-targeting cytotoxic antibiotic (8) . GO is indicated for the treatment of acute myeloid leukemia in elderly patients.
Active and passive targeting approaches have historically been pursued as separate strategies. However, there is evidence that antibodies do not necessarily require their target antigen to accumulate in tumor tissue (9, 10) . We recently observed that GO inhibited growth of CD33-negative human tumor xenografts in nude mice (11) . This finding suggested that antibodies not only targeted tumor tissue without requirement of the targeting antigen but also were capable of carrying sufficient amounts of calicheamicin to obtain therapeutic efficacy. Using only passive targeting of immunoglobulin to accumulate a cytotoxic agent in a tumor is rarely acknowledged as a feasible strategy for anticancer therapy.
Currently, we report that passive targeting of calicheamicin by means of immunoglobulin as a carrier causes tumor growth inhibition of a variety of human xenografts in nude mice, suggesting the feasibility of this strategy in cancer patients. Mechanistically, the anti-tumor efficacy of calicheamicin administered as a calicheamicin-immunoglobulin conjugate (CIgC) was related to the sensitivity of the tumor cells to the drug and depended on the use of an acid-labile linker between the drug and the immunoglobulin. Substitution of immunoglobulin as a carrier with either albumin or PEGylated Fc reduced or eliminated the efficacy of the conjugate. with an Amide (4-mercapto-4-methylpentanoic acid) linker to the antibodies. The molar ratio of calicheamicin to antibody showed a variation between 2:1 and 6:1 mol:mol. The chemical procedures for conjugation were published earlier (11, 16) . To PEGylate hP67.6, 50 mg of the antibody was mixed with 100 mg PEG [0.5 ml of 200 mg/ml of branched (10 kDa) 2 PEG stock] in 40 mM HEPES buffer pH 8.0, at a final protein Table I . CD33-expression on carcinoma and leukemia cells in vitro. 
Synthetic macromolecules (FcPEGL and FcPEGB
Relative median channel fluorescence using hP67.6 as primary antibody.
b No. of determinations. c Standard deviation of n determinations. d Relative median channel fluorescence using hP67.6-AcBut-CalichDMH as primary antibody.
e Non-small cell lung carcinoma. Cell lines with reMCF >4 are considered CD33-positive.
concentration of 10.6 mg/ml. The reaction was allowed to proceed at 20˚C for 60 min.
Flow cytometry. Aliquots of 10 5 cells were suspended in 100 μl phosphate-buffered saline supplemented with 1 % v/v bovine serum albumin. The cells were then incubated at 4˚C for 30 min in 10 μg/ml primary antibody (hP67.6, G5/44 or rituximab) or conjugates of these antibodies as specified in Results. Binding of the primary antibody to the cells was revealed by FITC/·-huIgG.
Determination of the ED 50 of hP67.6-AcBut-CalichDMH and CalichDMH in vitro.
A vital dye (MTS) staining was used to determine the number of surviving cells following exposure to various treatments. MTS (non-radioactive cell proliferation assay kit) was purchased from Promega (Madison, WI) and used according to the manufacturer's specifications. For each cell line a calibration curve (cell number versus optical density after 2 h) was established to estimate an appropriate initial seeding density. Cells were then seeded in 96-multiwell dishes at a density of 750-5,000 cells per well. Immediately after seeding, the cells were exposed to various concentrations (range 0-500 ng calicheamicin equivalents/ml) of hP67.6-AcBut-CalichDMH or CalichDMH. Following determination of the number of cells surviving 96 h of drug exposure, the ED 50 was calculated based on the logistic regression parameters derived from the dose-response curves. The ED 50 was defined as the concentration of drug (ng/ml CalichDMH) that caused a 50% reduction of the cell number after 96 h. Tables I and II were grown in Table II . Tumor volume reduction of CD33-negative xenografts following treatment with hP67.6-AcBut-CalichDMH.
Efficacy of calicheamicin conjugates in vivo. Subcutaneous tumors of cells specified in
where T is the average tumor volume of the hP67.6-AcBut-CalichDMH treated mice at a given time and C is the average tumor volume of the control mice at the same time.
b Nos. in italics indicate the amount of CalichDMH given per dose per mouse. All mice received a total of 3 doses. Treatment was given intraperitoneally at days 1, 5 and 9.
- 
Results
Design of calicheamicin conjugates. Calicheamicin analogues were conjugated to various carrier molecules by either acidlabile or acid-stabile linkers. The acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) or (3-acetylphenyl) acetic acid (AcPAc) linkers allow for acid hydrolysis of the hydrazone group followed by disulfide reduction (16, 18) . The acidstabile 4-mercapto-4-methyl-pentanoic acid (Amide) linker allows only for dissociation at the disulfide group (18) . The calicheamicin analogues, N-acetyl Á calicheamicin dimethyl hydrazide (CalichDMH) or N-acetyl Á calicheamicin dimethyl acid (CalichDMA) were conjugated with acid-labile or acidstabile linkers, respectively. The various conjugates will be designated as follows: 'carrier-linker-calicheamicin analogue'.
hP67.6-AcBut-CalichDMH inhibits growth of various subcutaneous xenografts despite undetectable amounts of the targeted antigen, CD33, on the tumor cells. The oncolytic effect of hP67.6-AcBut-CalichDMH was demonstrated in multiple xenograft models. Table I lists the carcinoma cell lines used to generate xenografts in nude mice and their expression of CD33 as measured by flow cytometry. The signal obtained using hP67.6 or hP67.6-AcBut-CalichDMH as primary antibody was in most instances similar to the signal obtained after using a negative control antibody, huIgG 4 . The relative median channel fluorescence (reMCF), which is the increase of the median channel fluorescence of a cell population probed with hP67.6 or hP67.6-AcBut-CalichDMH over that of a population probed with huIgG 4 , approximated 1 (maximum 3.1). In comparison, the reMCF of CD33-positive KG-1 myeloid leukemia cells was 9.1.
HP67.6-AcBut-CalichDMH inhibited tumor growth of A431 epidermoid carcinoma xenografts despite the absence of CD33 on the cell suface (Fig. 1) . All the groups of mice in the experiment were treated with a single intraperitoneal dose per mouse every 4 days for a period of 9 days (Q4Dx3). Mice with xenografts of approximately 80 mm 3 were treated. The growth of A431 xenografts was significantly (p<0.05) inhibited following administration of 3 doses of 4 μg hP67.6-AcButCalichDMH for up to 27 days after treatment. Xenografts treated with 2 μg/dose hP67.6-AcBut-CalichDMH were significantly (p<0.05) smaller than the controls at day 13 following the first injection (Fig. 1a) .
Administration of hP67.6-Amide-CalichDMA or Calich DMH at equivalent or higher doses than hP67.6-AcButCalichDMH did not inhibit tumor growth (Fig. 1b and c) . The results in Fig. 1 demonstrated not only a significant inhibition of tumor growth by hP67.6-AcBut-CalichDMH but also dependence of this effect on the linker used for conjugation. The ineffectiveness of CalichDMH indicates that release of calicheamicin from the conjugate in plasma is unlikely to cause the growth inhibition. To exclude the possibility that the efficacy of hP67.6-AcBut-CalichDMH was caused by slow release of CalichDMH from the peritoneum, the experiment was repeated using the intravenous route of administration of the drugs while maintaining the same dose, frequency and interval of the treatments. Significant growth inhibition was observed following treatment with hP67.6-AcBut-CalichDMH. Twenty-seven days following onset of therapy, the average tumor growth inhibition of mice treated with 2 or 4 μg/dose of this conjugate were 77 or 89%, respectively. Tumor growth inhibition [I % = 100X (1-T/C)] reflects reduction of the volume of treated tumors compared to controls. T stands for the average tumor volume of a group of mice that were treated with hP67.6-AcBut-CalichDMH and C is the average tumor volume of a control group. Both T and C were determined on the same day after treatment initiation. Intravenous administration of hP67.6-Amide-CalichDMA or CalichDMH did not yield significant tumor growth inhibition.
HP67.6-AcBut-CalichDMH inhibited tumor growth of human tumor xenografts from diverse histotypic origin (Table II) . The I %-values were derived from 27 independent experiments and were determined between 17 and 34 days after injection of the first dose of hP67.6-AcBut-CalichDMH. Despite variability in magnitude of the response, the data demonstrate that hP67.6-AcBut-CalichDMH at a dose of 4 μg/mouse (Q4Dx3) inhibits tumor growth in the majority of xenografts. Inhibition was also observed when lower amounts of the conjugate were administered. (Fig. 2) . This amount was expressed relative to the amount present in whole blood at the time of measurement (% Blood = 100 x Bq per gram tissue/Bq per gram blood) or relative to the total amount of conjugate given (% ID/g). Because of the blood-brain barrier, accumulation of the conjugate in the brain was not anticipated. Indeed, only a marginal amount of 125 Ilabeled conjugate was retained in the brain (% Blood = 3.5%) and this did not significantly vary within 96 h.
During a period of 96 h, the amount of hP67.6-AcButCalichDMH in tumor tissue relative to the amount in whole blood increased from 6 to 28%. This steady increase was exclusively found in tumor tissue. The % Blood-values of heart, intestine and spleen were highest at 2 h after injection and then steadily decreased with time. In liver and striated muscle, the peak of the % Blood-value was at 48 h. In skin, this value reached a plateau after 24 h. The increase of the % Bloodvalue in tumor tissue was not solely the indirect result of clearance of hP67.6-AcBut-CalichDMH from the blood but was also due to an increase of antibody concentration in tumor tissue. This was evidenced by a steady increase (doubling time = 151 h) of the % ID/g value, which indicates the absolute amount of hP67.6-AcBut-CalichDMH in the tissue. In contrast to tumor-tissue, the % ID/g decreased over time in all of the other tissues that we examined. Tumor tissue was thus exceptional in its capacity to retain and accumulate hP67.6-AcBut-CalichDMH. To verify whether tumor growth inhibition caused by hP67.6-AcBut-CalichDMH was restricted to hP67.6 as a carrier for passive targeting, we compared the efficacy of the hP67.6 conjugate to that of rituximab and G5/44 conjugates. HP67.6 and G5/44 are humanized IgG 4 molecules. Rituximab is a mouse-human IgG 1 chimera. G5/44 and rituximab recognize CD22 and CD20, respectively. None of the 3 antibodies bound with high avidity to N87 or MDAMB435/5T4. ReMCF values for hP67.6 are listed in Table I . The average reMCF values after probing N87 or MDAMB435/5T4 with rituximab were 1.41 and 0.89, respectively. After probing these cells with G5/44, the average reMCF values were respectively 0.76 and 1.85. Despite the poor binding of the antibodies to the cell lines, their calicheamicin conjugates caused significant (p<0.05) inhibition of tumor growth (Fig. 3) . The quantitative differences in efficacy among the various conjugates were rarely statistically significant (Fig. 3 legend) . Equivalent efficacy was thus achieved with the conjugates regardless of the specificity or isotype variant of the antibody used for conjugation. Fig. 4 indicated that for a calicheamicin conjugate to retain optimal efficacy, neither human serum albumin nor PEGylated Fc could replace the carrier antibody. Fig. 4a shows the growth inhibition by the MOPC-21-AcPAc-CalichDMH conjugate. MOPC-21 (15) is a mouse monoclonal antibody (IgG 1 ) with unknown specificity that is commonly used as negative control in immunodetection methods. The AcPAc linker was used to conjugate calicheamicin to this antibody. This conjugate's efficacy indicated that using the AcPAc linker did not prevent oncolytic effects of the conjugate. In comparison, the efficacy of HSA-AcPAc-CalichDMH was marginal within the same experiment (Fig. 4b) . Although this conjugate was more efficacious in another experiment (I=61% at 20 days after administration of 4 μg/mouse Q4Dx3), it did not have higher efficacy than the control antibody conjugate (I=77%). The requirement to use a complete immunoglobulin was further illustrated in Fig. 4c . In this experiment, we compared tumor growth inhibition by hP67.6-AcBut-CalichDMH to the efficacy of a conjugate consisting of a PEGylated Fc fragment linked to calicheamicin by an AcBut linker. Two types of PEG were used to increase the Stokes' radius of the conjugate. The FcPEGL (apparent MW = 300 kDa) was PEGylated with the linear N-hydroxysuccinimidyl ester of methoxy poly(ethylene glycol)propionic acid. FcPEGB was PEGylated with a branched form of this molecule (apparent MW = 250 kDa). Regardless of the nature of the PEG, the Fc conjugates failed to cause any growth inhibition. Alternatively, a complete PEGylated (branched PEG) antibody (hP67.6PEGB, apparent MW = 300 kDa) conjugated to calicheamicin inhibited tumor growth more than hP67.6-AcBut-CalichDMH, indicating that PEGylation per se did not abrogate the efficacy of a conjugate (Fig. 4d) .
Substituting the immunoglobulin by either human serum albumin (HSA) or PEGylated Fc fragments reduces the efficacy of calicheamicin conjugates. The data presented in
The efficacy caused by passive targeting of hP67.6-AcButCalichDMH correlates with the sensitivity of tumor cells to calicheamicin in vitro. The sensitivity of 10 tumor cell lines to CalichDMH and to hP67.6-AcBut-CalichDMH was tested in vitro. The ED 50 of these two drugs was defined as the lowest concentration (ng/ml) that reduced the number of cells in a monolayer after 96 h to 50% of an untreated control culture. The rank order of the various cell lines was similar whether ED 50 of CalichDMH or ED 50 of hP67.6-AcButCalichDMH was used as a ranking criterion (compare Fig. 5a with b). The linear regression coefficient of ED 50 of hP67.6-AcBut-CalichDMH as a function of ED 50 of CalichDMH was 0.79. The sensitivity of the subcutaneous xenografts to hP67.6-AcBut-CalichDMH was reflected by the maximum tumor growth inhibition (I max %). This parameter is the maximum I-value observed during a given experiment. Hence, the I max allowed a comparison of the efficacy of hP67.6-AcButCalichDMH on the various xenografts. Fig. 5 demonstrates that I max of these xenografts was inversely proportional to the ED 50 s determined after addition of CalichDMH (r=0.41, Fig. 5a ) or hP67.6-AcBut-CalichDMH (r=0.63, Fig. 5b ) to the cells from which the tumors originated. This crude correlation suggested that sensitivity to CalichDMH was a determinant for the efficacy of hP67.6-AcBut-CalichDMH. However, the exceptionally low I max found for LOVO colon carcinoma implied that sensitivity to CalichDMH alone was not sufficient to explain efficacy by passive targeting.
Discussion
The presented results show that calicheamicin-immunoglobulin conjugates cause tumor regression in various human tumor xenografts. These tumors did not display detectable amounts of antigen recognized by the immunoglobulin. Therefore, passive targeting of calicheamicin by means of an immunoglobulin carrier is a potential strategy to safely administer a therapeutically effective amount of calicheamicin.
By substituting immunoglobulin of the conjugate with other macromolecules, we identified carrier characteristics underlying the therapeutic activity of a CIgC. Consistent with the finding that accumulation of immunoglobulin in grafted tumors was more pronounced than the accumulation of albumin (9), we found that the antibody could neither be replaced by albumin nor by PEGylated Fc fragments without reducing efficacy of the conjugate. When administered Q4Dx3, calicheamicin conjugates of human IgG 1 (rituximab), human IgG 4 (hP67.6, G5/44) or mouse IgG 1 had similar efficacy. Thus, molecular weight and protein structure of the IgG molecule were necessary to target sufficient amounts of calicheamicin to the tumor without causing lethality in the mice. Since the isoelectric point of the carrier antibodies ranged from pH 6.0 (MOPC-21) to 9.0 (rituximab), our experiments did not substantiate an earlier prediction that the negative charge of the molecule would be a major determinant for its accumulation (9) .
Apart from the carrier function of the immunoglobulin, the use of an acid-labile linker (18) proved crucial for the efficacy of CIgC. This indicated that after accumulation of CIgC in the tumor, the pericellular acidic environment (19) was responsible for the release of calicheamicin. This mechanism was further inferred from the congruence of oncolytic effects by CIgC in vivo with the sensitivity of tumor cells to calicheamicin in vitro. We cannot exclude a contribution of pinocytosis as a mechanism for intracellular uptake of the CIgC. However, the observation that a CIgC constructed with an acid-stabile linker was ineffective in the absence of a targeted antigen renders the contribution of this mechanism less crucial.
We showed previously (11) that active targeting of calicheamicin to Le y was more efficacious than passive targeting. This manifested itself by shorter duration of the tumor remission and the higher doses necessary to obtain efficacy with a CIgC that uses a passive targeting mechanism. Yet, a passive targeting strategy may in certain circumstances be indicated because it bypasses the need for homogeneous (over)expression of a TAA. Furthermore, TAAs are rarely exclusive products of tumor cells. Expression of TAAs [e.g. Le y (20) , EGFR (21), Her2/neu (22) ] in normal tissues can pose therapeutic dose limiting toxicity for CIgC that recognize these antigens.
A CIgC with a carrier antibody that does not recognize any human antigen could theoretically bypass this problem. It should also be noted that comparisons between active and passive targeting with CIgC have been based on dose and regimen equivalence indicated by the amount of calicheamicin (11, 16) and not on the maximum tolerated dose. Theoretically, passive targeting may yield similar therapeutic indices as CIgCs that target TAAs because a reduced accumulation in the tumor could be compensated by a higher maximum tolerated dose. Unfortunately, this hypothesis can only be tested in the clinic since these CIgCs do not always recognize the mouse homologues of the targeted antigen.
Thus far, clinical trials that can determine efficacy of a CIgC designed for passive targeting have not been conducted. Nonetheless, the potential validity of this approach can be deduced from reports that show either accumulation of nonspecific IgG in tumors (10) or therapeutic response of a CIgC, GO, in patients whose cancer cells do not display the targeted antigen, CD33 (23) . Pancreatic tumors and liver metastases can be visualized by single photon emission computed tomography using non-specific IgG labeled with 111 In (10) . These clinical observations refute the notion that accumulation of 'non-specific' IgG in a tumor would be an artifact created in xenografts. The therapeutic responses to GO by CD33 -AML patients have been explained by endocytosis of the conjugate by malignant cells (23) , 'background' levels of CD33 (24) or the presence of a small subpopulation of CD33 + leukemic progenitors (24) . Because AML presents itself as a neovascularized tumor mass in bone marrow (25) , we propose a mechanism of passive targeting of the conjugate based on the EPR effect.
In conclusion, we have demonstrated that passive targeting of CIgCs yields therapeutic benefit in a variety of human tumor xenografts. We have also shown that characteristics of the IgG molecule and the use of an acid-labile linker were of quintessential importance to allow efficacy by passive targeting. CIgCs designed for passive targeting may prove to be valuable clinical assets in targeted delivery when tumors do not express tumor associated antigen or when extratumoral expression of these antigens prevents the use of actively targeted CIgC.
